Your browser doesn't support javascript.
loading
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
Wang, Yifan; Bernhardy, Andrea J; Cruz, Cristina; Krais, John J; Nacson, Joseph; Nicolas, Emmanuelle; Peri, Suraj; van der Gulden, Hanneke; van der Heijden, Ingrid; O'Brien, Shane W; Zhang, Yong; Harrell, Maribel I; Johnson, Shawn F; Candido Dos Reis, Francisco J; Pharoah, Paul D P; Karlan, Beth; Gourley, Charlie; Lambrechts, Diether; Chenevix-Trench, Georgia; Olsson, Håkan; Benitez, Javier J; Greene, Mark H; Gore, Martin; Nussbaum, Robert; Sadetzki, Siegal; Gayther, Simon A; Kjaer, Susanne K; D'Andrea, Alan D; Shapiro, Geoffrey I; Wiest, David L; Connolly, Denise C; Daly, Mary B; Swisher, Elizabeth M; Bouwman, Peter; Jonkers, Jos; Balmaña, Judith; Serra, Violeta; Johnson, Neil.
Afiliación
  • Wang Y; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Bernhardy AJ; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Cruz C; High Risk and Cancer Prevention Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Krais JJ; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Nacson J; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Nicolas E; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Peri S; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • van der Gulden H; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • van der Heijden I; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • O'Brien SW; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Zhang Y; Immune Cell Development and Host Defense Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Harrell MI; Department of Obstetrics and Gynecology and Medicine, University of Washington, Seattle, Washington.
  • Johnson SF; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Candido Dos Reis FJ; Department of Gynecology and Obstetrics, Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil. Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
  • Pharoah PD; Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
  • Karlan B; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
  • Gourley C; University of Edinburgh Cancer Research UK Centre, MRC IGMM, Edinburgh, United Kingdom.
  • Lambrechts D; VIB Vesalius Research Center, University of Leuven, Leuven, Belgium.
  • Chenevix-Trench G; QIMR Berghofer Medical Research Institute, Herston, Australia.
  • Olsson H; Departments of Cancer Epidemiology and Oncology, Lund University, Lund, Sweden.
  • Benitez JJ; Human Genetics Group and Human Genotyping Unit Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Greene MH; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
  • Gore M; Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Nussbaum R; University of California San Francisco, Cancer Risk Program, San Francisco, California.
  • Sadetzki S; Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel Hashomer, Israel.
  • Gayther SA; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.
  • Kjaer SK; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • D'Andrea AD; Department of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. Department of Pediatrics, Children's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Wiest DL; Immune Cell Development and Host Defense Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Connolly DC; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Daly MB; Risk Assessment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Swisher EM; Department of Obstetrics and Gynecology and Medicine, University of Washington, Seattle, Washington.
  • Bouwman P; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Jonkers J; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Balmaña J; High Risk and Cancer Prevention Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Johnson N; Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. neil.johnson@fccc.edu.
Cancer Res ; 76(9): 2778-90, 2016 05 01.
Article en En | MEDLINE | ID: mdl-27197267
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias de la Mama / Resistencia a Antineoplásicos / Proteína BRCA1 Idioma: En Revista: Cancer Res Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias de la Mama / Resistencia a Antineoplásicos / Proteína BRCA1 Idioma: En Revista: Cancer Res Año: 2016 Tipo del documento: Article